Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Monday, November 2, 2026

Back to the front page

BMRN Earnings Review

BioMarin’s Q3 revenue rose 32% to $1.02 billion after the Amicus acquisition, while lower 2026 guidance and $2.8 billion of net debt weighed on earnings.

BMRN $11B
Cestrian Capital Research 1 click

From X

@RagingVentures 1 click

Raging Capital Ventures on X

Along with our great guest speakers (outlined below), our Ideas & Networking Conference next Thursday, October 1st in NYC will feature a few investment ideas from yours truly. Over the years, we’ve highlighted some good ones, including: 2023 — $EFXT below $6, now $23+; $FPH below $3, now $4.65 2024 — Alphawave Semiconductor, subsequently acquired by $QCOM at a 70% premium; $MRAM below $6, now $18; $WBD below $9, now $30 2025 — Short $ORCL at $285 Plus, many more ideas along the way. We’re down to just a handful of seats for next week. Click below to register: https://t.co/NZIcFTuLGW
@convequity 1 click

Convequity on X

We’ve been mega-bullish on $PLTR since late 2020. We expected it to come out on top of our SaaS Survival Scorecard. It did. Most software will sit under someone else’s AI window. Palantir is one of the few that can reasonably be that window — the place where work, decisions, and data meet. The edge is breadth plus depth. Breadth: hundreds of kinds of operational work on one substrate, not one app. Depth: it reaches down into the source data layer. A lot of the records still live in old ERP and CRM systems. Palantir doesn’t have to own those databases. It normalizes the mess, puts a shared map on top — objects, relationships, allowed actions — and that map becomes the ground truth. Think of SAP and Salesforce as the ground floor. Palantir is floor 1: where the business actually runs. That creates data gravity and speed. Once decisions live on floor 1, going around Palantir is the hard path. One thing that is not a proven Palantir product yet is refining models on the customer’s own missions — post-training and reinforcement learning on their data, with the customer keeping the weights. That is the NVIDIA Nemotron work. Until recently it was a partnership. Two weeks ago at AIPCon 11, NVIDIA showed it live in its own supply chain. That’s the first public install. Not a general customer rollout. A few months ago the stock was subdued even after strong results, on the fear that model labs would expand into Palantir’s territory. A working Nemotron collaboration takes some of that risk off the table. The risk now is different: Nemotron has to become a frontier-quality model. If it does, Palantir is the best — and probably the only — company positioned to deliver true sovereignty over enterprise intelligence. If it isn’t smart enough, post-training and RL on Palantir’s stack may still not be good enough for enterprises. Watch two windows for Nemotron progress. The nearer one is Q3 earnings commentary — Palantir usually reports that quarter in early November. Management may say more there. The other is the next AIPCon, Palantir’s customer case-study day, roughly every quarter - possibly early December. That’s where live customer proof will show up.

Investor Letters

All letters

Altria: Dutiful

Altria raised 2026 adjusted EPS guidance to $5.66 to $5.74 and authorized more buybacks, while on! loses share as cigarette margins hold.

MO $130B
Invariant 3 clicks
BR · long

Broadridge Financial Solutns

Broadridge Financial Solutions is framed as a high and rising free-cash-flow generator at a depressed valuation, with insider buying…

BR $21B
Value Investors Club

FTAI 3Q26: Aero margins in focus

FTAI’s Aerospace Products margin rebounded to 31% as CFM56 module output rose, while Power deposits and contracted deliveries fund its 2027…

FTAI $20B
Stock Thoughts 5 clicks

CVX Earnings Review

Chevron’s Q3 revenue rose 35% to $65.2 billion and EBITDA 75% to $20.2 billion, while production trailed guidance and refining margins…

CVX $423B
Cestrian Capital Research 4 clicks

SNY Earnings Review

Sanofi raised FY26 guidance after Q3 sales grew 14.3% at constant currency, led by 34.8% Dupixent growth; vaccines declined 6.6%.

SNY $114B
Cestrian Capital Research 1 click

TSOH Weekly Roundup (10/30/2026)

Markel spent $315 million repurchasing shares in Q3 as Thrive agreed to buy ADT for $7.6 billion and Hasbro cited rising adult toy demand.

MKL $24B
TSOH Investment Research 1 click

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 74 of 275

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.